Experience from the Argentine Pegvisomant Observational Study: Preliminary Data

N. García Basavilbaso,Mirtha Guitelman,A Nagelberg,Graciela Stalldecker,A. Carabelli,Oscar D. Bruno,K. Danilowitz,Marcos Manavela,S. Mallea Gil,Carolina Ballarino,R. Guelman,David F. Katz,S. Fidalgo,Rodolfo Oliveira Leal,Hugo L. Fideleff,Marisa Servidio,D. Bruera,F. Librandi,Alberto Chervin,M. Vitale,Armando Basso

Experience from the Argentine Pegvisomant Observational Study: Preliminary Data

2010

The GH receptor antagonist pegvisomant is an efficient agent to achieve biochemical control of acromegaly in those cases refractory to surgery and medical therapy with somatostatin analogs. We conduct

Keywords:

Internal medicine
Endocrinology
Somatostatin
Observational study
GH Receptor
Pegvisomant
Acromegaly
Adverse effect
Medicine
Refractory
Antagonist
medical therapy
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations